BRM:FRA
Bristol-Myers Squibb Co
€58.25
arrow_upward
+0.80%(+0.46) 1D
Sep 4, 8:25:23 AM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BRM...
Open
€58.25
High
€58.25
Low
€58.25
Mkt. cap
139.09B
Avg. vol.
481.00
Volume
0.00
52-wk high
€60.64
52-wk low
€36.65
No. of employees
32K
Open
€58.25
High
€58.25
Low
€58.25
Mkt. cap
139.09B
Avg. vol.
481.00
Volume
0.00
52-wk high
€60.64
52-wk low
€36.65
No. of employees
32K
News stories
From web sources and news partners
Seeking Alpha
·
1 hour ago
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY)
Building Indiana Business
·
2 hours ago
RayzeBio Plans $173M Expansion in Indiana’s Life Sciences Sector
MarketBeat
·
3 hours ago
Nykredit A S Purchases New Shares in Bristol Myers Squibb Company $BMY
AD HOC NEWS
·
7 hours ago
Bristol Myers Squibb stock gains on Q2 beat and raised 2026 guidance
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Co
CEOChris Boerner
Employees32.5K
Founded1887
HeadquartersNew York, New York, United States
SectorPharmaceutical industry
Websitebms.com